Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTR3A | P46098 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408819 | 0.88 | NR4A2 (1.00) | NR4A2ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL15557161 | 0.85 | NR4A2 (0.72) | NR4A2ALDH1A1KDM4ELMNAHTR3A | |
| SCHEMBL15444634 | 0.84 | NR4A2 (0.55) | NR4A2ALDH1A1KDM4ELMNAHTR3A | |
| SCHEMBL25238096 | 0.84 | NR4A2 (0.75) | NR4A2ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL19407224 | 0.83 | NR4A2 (0.79) | NR4A2ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL25307454 | 0.83 | NR4A2 (0.79) | NR4A2ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL15421267 | 0.82 | NR4A2 (0.56) | NR4A2KDM4ELMNAHTR3A | |
| SCHEMBL3681206 | 0.82 | NR4A2 (0.68) | NR4A2ALDH1A1KDM4ELMNAHTR3A | |
| SCHEMBL4068109 | 0.81 | KCNH2 (0.53) | NR4A2ALDH1A1KDM4ELMNAHTR3A | |
| SCHEMBL23812575 | 0.81 | KMT2A (0.53) | NR4A2ALDH1A1LMNAHTR3AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312169-B1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-09-15 | — | — | EP | disclosed |
| US-10407443-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| CN-106478662-B | 5-HT3 receptor antagonist | 武田药品工业株式会社 | 2019-07-02 | — | — | CN | disclosed |
| US-20180327421-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-10125145-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3312169-A1 | 5-HT3 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9670229-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-06 | — | — | US | disclosed |
| CN-106478662-A | 5 HT3 receptor antagonists | 武田药品工业株式会社 | 2017-03-08 | — | — | CN | disclosed |
| CN-104768943-B | 5-HT3 receptor antagonists | 武田药品工业株式会社 | 2016-11-16 | — | — | CN | disclosed |
| US-20160251373-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-9346829-B2 | 5-HT3 receptor antagonists | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| CN-104768943-A | 5-ht3 receptor antagonists | TAKEDA PHARMACEUTICAL | 2015-07-08 | — | — | CN | disclosed |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-2875011-A1 | 5-HT3 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-9012447-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-21 | — | — | US | disclosed |
| WO-2014014951-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407443-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | NR4A2 1436/4885ALDH1A1 1329/4885KDM4E 4085/4885 |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | NR4A2 1436/4885ALDH1A1 1329/4885KDM4E 4085/4885 |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR3E | NR4A2 801/4885ALDH1A1 1138/4885KDM4E 2481/4885 |
| US-20180327421-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | NR4A2 1436/4885ALDH1A1 1329/4885KDM4E 4085/4885 |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | NR4A2 1436/4885ALDH1A1 1329/4885KDM4E 4085/4885 |
| US-20160251373-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | NR4A2 1436/4885ALDH1A1 1329/4885KDM4E 4085/4885 |
| US-10125145-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | NR4A2 1436/4885ALDH1A1 1329/4885KDM4E 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.